Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Genocea Biosciences, Inc.    GNCA

GENOCEA BIOSCIENCES, INC.

(GNCA)
Add to my list
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/11/2021 01/12/2021 01/13/2021 01/14/2021 01/15/2021 Date
2.38(c) 2.45(c) 3.07(c) 2.95(c) 2.71(c) Last
256 506 431 560 3 114 293 666 278 546 899 Volume
-2.06% +2.94% +25.31% -3.91% -8.14% Change
More quotes
Financials (USD)
Sales 2020 1,40 M - -
Net income 2020 -41,5 M - -
Net cash position 2020 61,0 M - -
P/E ratio 2020 -2,85x
Yield 2020 -
Sales 2021 0,45 M - -
Net income 2021 -53,2 M - -
Net cash position 2021 76,0 M - -
P/E ratio 2021 -3,19x
Yield 2021 -
Capitalization 140 M 140 M -
EV / Sales 2020 56,4x
EV / Sales 2021 142x
Nbr of Employees 59
Free-Float 93,0%
More Financials
Company
Genocea Biosciences, Inc. is a biopharmaceutical company developing personalized cancer immunotherapies. The Company’s Antigen Lead Acquisition System (ATLAS) technology platform allows to identify targets based on each person’s tumor antigen-specific T cell responses. Using ATLAS, the Company can improve neoantigens for inclusion in its immunotherapies and exclude inhibitory antigens that exert an... 
More about the company
Notations Surperformance© of Genocea Biosciences, Inc.
Trading Rating : Investor Rating : -
More Ratings
All news about GENOCEA BIOSCIENCES, INC.
01/04GENOCEA BIOSCIENCES, INC. : Regulation FD Disclosure (form 8-K)
AQ
01/04Genocea to Present at the H.C. Wainwright Virtual BioConnect Conference
GL
2020GENOCEA BIOSCIENCES, INC. : Regulation FD Disclosure, Financial Statements and E..
AQ
2020GENOCEA BIOSCIENCES : to Present at the Stifel 2020 Virtual Healthcare Conferenc..
AQ
2020GENOCEA BIOSCIENCES : to Present at the Stifel 2020 Virtual Healthcare Conferenc..
AQ
2020Genocea to Present at the Stifel 2020 Virtual Healthcare Conference
GL
2020GENOCEA BIOSCIENCES, INC. : Regulation FD Disclosure, Financial Statements and E..
AQ
2020GENOCEA BIOSCIENCES, INC. : Regulation FD Disclosure, Financial Statements and E..
AQ
2020GENOCEA BIOSCIENCES : Presents Positive GEN-009 Clinical Results, Update on GEN-..
AQ
2020Genocea Presents Positive GEN-009 Clinical Results, Update on GEN-011 Program..
GL
2020GENOCEA BIOSCIENCES : to Host Investor Call Highlighting New GEN-009 Clinical an..
AQ
2020Genocea to Host Investor Call Highlighting New GEN-009 Clinical and Immunogen..
GL
2020GENOCEA BIOSCIENCES : Management's Discussion and Analysis of Financial Conditio..
AQ
2020GENOCEA BIOSCIENCES : 3Q Earnings Snapshot
AQ
2020GENOCEA BIOSCIENCES, INC. : Results of Operations and Financial Condition, Finan..
AQ
More news
News in other languages on GENOCEA BIOSCIENCES, INC.

- No features available -

More news
Chart GENOCEA BIOSCIENCES, INC.
Duration : Period :
Genocea Biosciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GENOCEA BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Average target price 6,60 $
Last Close Price 2,71 $
Spread / Highest target 232%
Spread / Average Target 144%
Spread / Lowest Target 47,6%
EPS Revisions
Managers and Directors
NameTitle
William D. Clark President, Chief Executive Officer & Director
Kenneth M. Bate Chairman
Diantha Duvall Chief Financial Officer
Jessica Baker Flechtner Chief Scientific Officer
Thomas Andrew Davis Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
GENOCEA BIOSCIENCES, INC.11.98%140
MODERNA, INC.24.10%51 304
LONZA GROUP AG3.27%49 041
CELLTRION, INC.-8.36%40 715
IQVIA HOLDINGS INC.4.81%36 004
SEAGEN INC.6.06%33 601